Literature DB >> 30241603

Mechanism for Synthetic Lethality in BRCA-Deficient Cancers: No Longer Lagging Behind.

Niek van Wietmarschen1, Andre Nussenzweig2.   

Abstract

Two recent studies implicate PARP as sensors of incompletely processed Okazaki fragments, changing our view about how single-strand breaks arise in unperturbed cells. Unligated Okazaki fragments may trigger homologous recombination-mediated repair and underpin genome instability in BRCA1/BRCA2-deficient cancers. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30241603      PMCID： PMC6589159          DOI： 10.1016/j.molcel.2018.08.045

Source DB:  PubMed          Journal:  Mol Cell        ISSN： 1097-2765            Impact factor:   17.970


  8 in total

1.  Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress.

Authors:  Tao Han; Jing Tong; Mengxin Wang; Yu Gan; Bo Gao; Jiaxiang Chen; Youxun Liu; Qian Hao; Xiang Zhou
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

2.  GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.

Authors:  Mary M Mullen; Elena Lomonosova; Michael D Toboni; Alyssa Oplt; Emily Cybulla; Barbara Blachut; Peinan Zhao; Hollie Noia; Daniel Wilke; Erinn B Rankin; Lindsay M Kuroki; Andrea R Hagemann; Ian S Hagemann; Carolyn K McCourt; Premal H Thaker; David G Mutch; Matthew A Powell; Nima Mosammaparast; Alessandro Vindigni; Katherine C Fuh
Journal:  Mol Cancer Res       Date:  2021-10-20       Impact factor: 6.333

Review 3.  Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.

Authors:  Dae-Seok Kim; Cristel V Camacho; W Lee Kraus
Journal:  Exp Mol Med       Date:  2021-01-25       Impact factor: 8.718

Review 4.  Opinion: PARP inhibitors in cancer-what do we still need to know?

Authors:  Andrew J Wicks; Dragomir B Krastev; Stephen J Pettitt; Andrew N J Tutt; Christopher J Lord
Journal:  Open Biol       Date:  2022-07-27       Impact factor: 7.124

Review 5.  PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.

Authors:  Dongha Kim; Hye Jin Nam
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

Review 6.  PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.

Authors:  Nannan Wang; Yan Yang; Dongdong Jin; Zhenan Zhang; Ke Shen; Jing Yang; Huanhuan Chen; Xinyue Zhao; Li Yang; Huaiwu Lu
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

7.  Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.

Authors:  Ke Cong; Min Peng; Arne Nedergaard Kousholt; Wei Ting C Lee; Silviana Lee; Sumeet Nayak; John Krais; Pamela S VanderVere-Carozza; Katherine S Pawelczak; Jennifer Calvo; Nicholas J Panzarino; John J Turchi; Neil Johnson; Jos Jonkers; Eli Rothenberg; Sharon B Cantor
Journal:  Mol Cell       Date:  2021-07-02       Impact factor: 19.328

8.  The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells.

Authors:  Antoine Simoneau; Rosalinda Xiong; Lee Zou
Journal:  Genes Dev       Date:  2021-08-12       Impact factor: 11.361
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.